.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Express Scripts
Daiichi Sankyo
McKesson
Queensland Health
Moodys
Fish and Richardson
Mallinckrodt
AstraZeneca
Merck

Generated: September 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 018440

« Back to Dashboard
NDA 018440 describes M.V.C. 9+3, which is a drug marketed by Abraxis Pharm and is included in one NDA. Additional details are available on the M.V.C. 9+3 profile page.

The generic ingredient in M.V.C. 9+3 is ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine hydrochloride; riboflavin 5'-phosphate sodium; thiamine hydrochloride; vitamin a; vitamin e. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine hydrochloride; riboflavin 5'-phosphate sodium; thiamine hydrochloride; vitamin a; vitamin e profile page.

Summary for NDA: 018440

You have an error in your SQL syntax; check the manual that corresponds to your MariaDB server version for the right syntax to use near 'SODIUM','THIAMINE HYDROCHLORIDE','VITAMIN A','VITAMIN E') AND hsdb_drugname IS N' at line 1
Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0